Kamada (KMDA) said Wednesday it was awarded a contract with an unnamed international organization to supply Kamrab and Varizig in Latin America for the 2025-2027 period.
Revenue under the three-year contract is expected to be about $25 million, the company said.
Kamrab is indicated for the prevention of rabies infection after contact with rabid or possibly rabid animals, while Varizig is a varicella drug for post-exposure prophylaxis in high-risk individuals, Kamada said.
The company's shares were rising past 5% in recent trading.
Price: 7.48, Change: +0.40, Percent Change: +5.64
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。